05 September 2025, Geneva – Today, the World Health Organization (WHO) has released updated editions of its Model Lists of Essential Medicines (EML) and Essential Medicines for Children (EMLc), adding new treatments for various types of cancer and for diabetes with associated comorbidities such as obesity. Medicines for cystic fibrosis, psoriasis, haemophilia and blood-related disorders are among the other additions.
WHO EML and EMLc include medicines for the priority health needs of populations. They are adopted in over 150 countries, serving as a basis for public sector procurement, supply of medicines, and health insurance and reimbursement schemes. The revisions mark the 24th edition of WHO EML and the 10th edition of EMLc.
“The new editions of essential medicines lists mark a significant step toward expanding access to new medicines with proven clinical benefits and with high potential for global public health impact,” said Dr Yukiko Nakatani, Assistant Director-General for Health Systems, Access and Data.
Launched in 1977 largely to promote better access to medicines in developing countries, the WHO Model Lists have become a trusted global policy tool for decisions related to the selection and universal coverage of medicines within all health systems.
The WHO Expert Committee on the Selection and Use of Essential Medicines reviewed 59 applications, including 31 proposals for the addition of new medicines or medicine classes. As a result, 20 new medicines were added to the EML and 15 to the EMLc, along with new use indications for seven already-listed products. The updated lists now include a total of 523 essential medicines for adults and 374 for children, reflecting the most pressing public health needs.
Cancer is the second leading cause of death globally, claiming nearly 10 million lives each year and responsible for almost one in three premature deaths from noncommunicable diseases. Cancer treatments have been a major focus of the WHO EML for the past decade. With cancer medicines accounting today for about half of all new drug approvals by regulatory agencies, the Expert Committee applies rigorous criteria to recommend only those therapies that offer the greatest clinical benefit. As a result, few approved cancer medicines are included – only those proven to prolong life by at least 4 to 6 months.
Seven applications encompassing 25 cancer medicines were evaluated. As part of broader efforts to reduce inequities in cancer care, the Committee recommended increasing access to PD-1/PD-L1 immune checkpoint inhibitors, a class of immunotherapy medicines that help the body’s immune system recognize and attack cancer cells more effectively. Pembrolizumab was added to the EML as a first-line monotherapy for metastatic cervical cancer, metastatic colorectal cancer, and metastatic non-small cell lung cancer. For the latter, atezolizumab and cemiplimab are included as therapeutic alternatives.
The Committee also considered several expert-recommended strategies – highlighted in the cancer experts' report – aimed at improving access to and affordability of cancer treatments. It endorsed evidence-based clinical and health system strategies, including dose optimisation approaches, to improve access. The Committee emphasized that while health system reforms require time and government action, clinical strategies can be implemented immediately to deliver faster benefits, especially in resource-limited settings.
Diabetes and obesity are two of the most urgent health challenges facing the world today. Over 800 million people were living with diabetes in 2022, with half going untreated. At the same time, more than 1 billion people worldwide are affected by obesity, and rates are rising especially fast in low- and middle-income countries. These two conditions are closely linked and can lead to serious health problems, including heart disease and kidney failure.
The WHO Expert Committee reviewed strong scientific evidence showing that a group of medicines called glucagon-like peptide-1 (GLP-1) receptor agonists can help people with type 2 diabetes – especially those who also have heart or kidney disease – by improving blood sugar control, reducing the risk of heart and kidney complications, supporting weight loss, and even lowering the risk of early death.
GLP-1 receptor agonists – semaglutide, dulaglutide and liraglutide – and the GLP-1/glucose-dependent insulinotropic polypeptide (GIP) dual receptor agonist (tirzepatide) have been added to the EML. They are used as glucose-lowering therapy for adults with type 2 diabetes mellitus with established cardiovascular disease or chronic kidney disease and obesity (defined as body mass index (BMI) ≥ 30kg/m2). This provides clear guidance to countries on which patients can benefit most from these therapies.
High prices of medicines like semaglutide and tirzepatide are limiting access to these medicines. Prioritizing those who would benefit most, encouraging generic competition to drive down prices and making these treatments available in primary care – especially in underserved areas – are key to expanding access and improving health outcomes. WHO will continue monitoring developments, support fair pricing strategies, and help countries improve access to these life-changing treatments.
“A large share of out-of-pocket spending on noncommunicable diseases goes toward medicines, including those classified as essential and that, in principle, should be financially accessible to everyone,” said Deusdedit Mubangizi, WHO Director of Policy and Standards for Medicines and Health Products. “Achieving equitable access to essential medicines requires a coherent health system response backed by strong political will, multisectoral cooperation, and people-centred programmes that leave no one behind.”
More details of the Expert Committee’s recommendations, describing the additions, changes and removal of medicines and formulations, and decisions not to recommend medicines are available in the Executive Summary here.
04 September 2025---Kinshasa – Health authorities in the Democratic Republic of the Congo have declared an outbreak of Ebola virus disease in Kasai Province where 28 suspected cases and 15 deaths, including four health workers, have been reported as of 4 September 2025.
The outbreak has affected Bulape and Mweka health zones in Kasai Province where health officials have been carrying out investigations after the cases and the deaths reported presented with symptoms including fever, vomiting, diarrhoea and haemorrhage. Samples tested on 3 September at the country’s National Institute of Biomedical Research in the capital Kinshasa confirmed the cause of the outbreak as Ebola Zaire caused by Ebola virus disease.
A national Rapid Response Team joined by World Health Organization (WHO) experts in epidemiology, infection prevention and control, laboratory and case management has been deployed to Kasai Province to rapidly strengthen disease surveillance, treatment and infection prevention and control in health facilities. Provincial risk communication experts have also been deployed to reach communities and help them understand how to protect themselves.
Additionally, WHO is delivering two tonnes of supplies including personal protective equipment, mobile laboratory equipment and medical supplies. The area is difficult to reach, taking at least one day of driving from Tshikapa (the provincial capital of Kasai), with few air links.
“We’re acting with determination to rapidly halt the spread of the virus and protect communities,” said Dr Mohamed Janabi, WHO Regional Director for Africa. “Banking on the country’s long-standing expertise in controlling viral disease outbreaks, we’re working closely with the health authorities to quickly scale up key response measures to end the outbreak as soon as possible.”
Case numbers are likely to increase as the transmission is ongoing. Response teams and local teams will work to find the people who may be infected and need to receive care, to ensure everyone is protected as quickly as possible.
The country has a stockpile of treatments, as well as 2000 doses of the Ervebo Ebola vaccine, effective to protect against this type of Ebola, already prepositioned in Kinshasa that will be quickly moved to Kasai to vaccinate contacts and frontline health workers.
The Democratic Republic of the Congo’s last outbreak of Ebola virus disease affected the north-western Equateur province in April 2022. It was brought under control in under three months thanks to the robust efforts of the health authorities. In Kasai province, previous outbreaks of Ebola virus disease were reported in 2007 and 2008. In the country overall, there have been 15 outbreaks since the disease was first identified in 1976.
Ebola virus disease is a rare but severe, often fatal illness in humans. It is transmitted to people through close contact with the blood, secretions, organs or other bodily fluids of infected animals such as fruit bats (thought to be the natural hosts). Human-to-human transmission is through direct contact with blood or body fluids of a person who is sick with or has died from Ebola, objects that have been contaminated with body fluids from a person sick with Ebola or the body of a person who died from Ebola.
22 August 2025, Geneva –The World Health Organization (WHO) and the World Meteorological Organization (WMO) have published a new joint report and guidance highlighting the growing global health challenges posed by extreme heat on workers.
As climate change drives more frequent and intense heatwaves, many workers who are regularly exposed to dangerous heat conditions are already feeling the health impacts of rising temperatures, in particular, manual workers in sectors such as agriculture, construction and fisheries. Increasing heat episodes are also leading to health issues for vulnerable populations in developing countries, such as children, older adults and low-income populations.
“Heat stress is already harming the health and livelihoods of billions of workers, especially in the most vulnerable communities,” said Dr Jeremy Farrar, WHO Assistant Director-General, Health Promotion, Disease Prevention and Care. “This new guidance offers practical, evidence-based solutions to protect lives, reduce inequality, and build more resilient workforces in a warming world.”
The new report and technical guidance, entitled Climate change and workplace heat stress draws on five decades of research and evidence, highlighting that the health and productivity of workers are severely impacted by rising temperatures. WMO reports that 2024 was the hottest year on record. Daytime temperatures of more than 40°C and even above 50°C are becoming increasingly common, a clear indication that immediate action is needed to address the worsening impact of heat stress on workers worldwide.
“Occupational heat stress has become a global societal challenge, which is no longer confined to countries located close to the equator – as highlighted by the recent heatwave in Europe,” said WMO Deputy Secretary-General Ko Barrett. “Protection of workers from extreme heat is not just a health imperative but an economic necessity.”
Key findings
The report and guidance outline key issues related to the health impacts of extreme heat.
To tackle these challenges, the report calls for the implementation of occupational heat action plans, tailored to specific industries and regions, and developed in collaboration with employers, workers, unions, and public health experts.
Recommended actions
The guidance lays out a clear path for governments, employers, and health authorities to mitigate the growing risks of extreme heat on working populations. The recommended actions include:
The report and technical guidance by WHO and WMO complement the findings of the recent International Labour Organization (ILO) reports, which highlight that more than 2.4 billion workers are exposed to excessive heat globally, resulting in over 22.85 million occupational injuries each year.
“This report represents a critical milestone in our collective response to the growing threat of extreme heat in the world of work,” said Joaquim Pintado Nunes, ILO’s Chief of Occupational Safety and Health and the Working Environment. “Aligned with the ILO’s mandate to promote safe and healthy working environments as a fundamental right, it offers robust, evidence-based guidance to help governments, employers and workers confront the escalating risks of climate change. Together with WHO and WMO, we call for urgent, coordinated action to safeguard the health, safety and dignity of the more than 2.4 billion workers exposed to excessive heat worldwide.”
Call to action
This guidance serves as a critical resource for policymakers, public health officials, and employers in mitigating the escalating impact of workplace heat stress. It aligns with key United Nations Sustainable Development Goals, calling for decisive actions that protect vulnerable workers, reduce poverty, and promote sustainable economic growth. Immediate implementation of policies and programmes that safeguard worker health and productivity in the face of climate change is essential.
In the context of the accelerating climate crisis, this guidance serves as a vital tool to help countries respond decisively, protecting lives, livelihoods and economies from the growing threat of extreme heat.
Speakers were:
Rüdiger Krech, Director a.i., Environment, Climate Change and Health, WHO; Johan Stander, Senior Director, WMO Services Division; Joaquim Pintado Nunes, Chief of Occupational Safety and Health and the Working Environment, International Labour Organization (ILO); Joy Shumake-Guillemot, Lead of the WHO/WMO Joint Office for Climate and Health; Ivan Ivanov, Lead of the Occupational and Workplace Health Programme, WHO; and Andreas Flouris, professor at the University of Thessaly, Greece and main editor of the WHO/WMO joint report.
Media contacts:
WMO – media@wmo.int
WHO – mediainquiries@who.int
New Delhi | 18 August 2025: The World Health Organization today announced Nepal has eliminated rubella as a public health problem, a remarkable achievement for a country making concerted efforts to protect its people from vaccine preventable diseases.
Rubella, or German measles, is a highly contagious viral infection. It is particularly serious for pregnant women as infection can lead to miscarriage, stillbirth, or a range of lifelong and debilitating birth defects. But rubella is preventable with safe and cost-effective vaccines.
“Nepal’s success reflects the unwavering commitment of its leadership, persistent efforts of the health care workers and volunteers, and unstinting support of engaged and informed communities, for a healthy start for babies and a future free of rubella disease,” said Dr Catharina Boehme, Officer-In-Charge WHO South-East Asia, while endorsing the recommendation of the Regional Verification Commission for Measles and Rubella elimination in South-East Asia Region (SEA-RVC) for Nepal to be verified for eliminating rubella.
The SEA-RVC which held its annual meeting from 22-24 July 2025, reviewed and evaluated information and data submitted by the national verification committee on measles and rubella disease surveillance and immunization coverage rates, and recommended verification of rubella elimination in Nepal.
Nepal is the sixth country in WHO South-East Asia to achieve rubella elimination. Prioritizing elimination of measles and rubella as public health problems in WHO South-East Asia by 2026, Bhutan, DPR Korea, Maldives, and Timor-Leste have eliminated measles, and Bhutan, DPR Korea, Maldives, Sri Lanka, Timor-Leste, and now Nepal, have eliminated rubella.
“Nepal’s achievement of rubella elimination is yet another testament to the success of the national immunization program ahead of the regional target, which has long been one of the strongest pillars of our health care system. Gavi and WHO’s steadfast support to the programme and the overall health sector in Nepal is deeply valued and acknowledged. I take this moment to thank and congratulate all the leaders, health workers, volunteers and community members who’ve contributed to this achievement. And I call upon all stakeholders to continue their unwavering support so that no child in Nepal has to suffer from a vaccine-preventable disease,” said Mr Pradip Paudel, Minister of Health and Population, Nepal.
Nepal introduced rubella-containing vaccine in its immunization programme in 2012 with a nationwide campaign for age group 9 months to 15 years. A second dose of rubella-containing vaccine was added to the routine immunization schedule in 2016.
Four national campaigns with rubella vaccines in 2012, 2016, 2020, and 2024, helped increase access, despite major public health emergencies such as the COVID-19 pandemic and earthquakes in 2015 and 2023. By 2024, Nepal achieved over 95% coverage for at least one dose of rubella vaccine.
Innovative strategies such as observing ‘immunization month’, outreach to vaccinate missed children, and motivation for the districts to be declared ‘fully immunized’, provided further impetus to elimination efforts.
To further strengthen surveillance, Nepal recently introduced a robust laboratory testing algorithm, the first in the WHO South-East Asia Region to do so.
“Congratulations to Nepal for eliminating rubella. This public health achievement is the result of close collaboration between the government, dedicated health workers, partners and communities. WHO is proud to have contributed to this journey and remains committed to supporting Nepal sustain this accomplishment,” said Dr Rajesh Sambhajirao Pandav, WHO Representative to Nepal.
8 August 2025 -- Nairobi, Brazzaville, Geneva -- The World Health Organization (WHO) has validated Kenya as having eliminated human African trypanosomiasis (HAT) or sleeping sickness as a public health problem, making it the tenth country to reach this important milestone. HAT is the second neglected tropical disease (NTD) to be eliminated in Kenya: the country was certified free of Guinea worm disease in 2018.
“I congratulate the government and people of Kenya on this landmark achievement,” said Dr Tedros Adhanom Ghebreyesus, WHO Director-General. “Kenya joins the growing ranks of countries freeing their populations of human African trypanosomiasis. This is another step towards making Africa free of neglected tropical diseases”.
HAT is a vector-borne disease caused by the blood parasite Trypanosoma brucei. It is transmitted to humans through the bites of tsetse flies that have acquired the parasites from infected humans or animals. Rural populations dependent on agriculture, fishing, animal husbandry or hunting are most at risk of exposure.
As the name indicates, HAT is transmitted only on the African continent. The disease exists in two forms, gambiense and rhodesiense. The rhodesiense form (r-HAT), which is found in eastern and southern Africa, is the only one present in Kenya. It is caused by Trypanosoma brucei rhodesiense and progresses rapidly, invading multiple organs including the brain. Without treatment, it is fatal within weeks.
“This validation marks a major public health milestone for Kenya, as we celebrate the elimination of a deadly disease in our country. The achievement will not only protect our people but also pave the way for renewed economic growth and prosperity,” said Dr Aden Duale, Kenya’s Cabinet Secretary for Health. “This follows many years of dedication, hard work and collaboration”.
The first cases of HAT in Kenya were detected in the early 20th century. Since then, Kenya has engaged in consistent control activities, without indigenous new cases reported for over 10 years. The last autochthonous case was detected in 2009, and the last two exported cases, infected in the Masai Mara National Reserve, were detected in 2012.
Recently, Kenya strengthened HAT surveillance in 12 health facilities in six historically endemic counties to act as sentinel sites. They were equipped with diagnostic tools and had their clinical personnel trained on diagnostic procedures, including the most sensitive and practical tests for r-HAT. The country also actively monitors the control and surveillance of tsetse flies and animal trypanosomiasis, both within and beyond the historical HAT endemic areas, supported by the national veterinary health authorities and the Kenya Tsetse and Trypanosomiasis Eradication Council (KENTTEC). These activities and the related data provide supplementary backing to the claim of HAT elimination as a public health problem.
“This key milestone reflects Kenya’s efforts and commitment over many years, as a collaboration between national and county governments, national research institutions, development partners and affected communities,” said Dr Patrick Amoth, EBS, Director General Health, Ministry of Health, Kenya. “The country remains fully committed to sustain the quality of care and surveillance in line with WHO’s recommendations”.
Supported by WHO and partners, including FIND, Kenya’s HAT elimination programme will now implement a post-validation surveillance plan to detect any potential resurgence or reintroduction of transmission. WHO continues to support ongoing monitoring in previously affected areas and maintains a stock of medicines to ensure rapid treatment of possible future cases, thanks to donations from Bayer AG and Sanofi.
“This success was made possible by the Ministry of Health’s leadership, the dedication of health workers in areas at risk and the support from key partners,” said Dr Abdourahmane Diallo, WHO Representative to Kenya. “WHO is proud to have contributed to this achievement and encourages all stakeholders to remain involved in post-validation monitoring”.
A total of 57 countries have eliminated at least one NTD. Of these, 10 (including Kenya) have successfully eliminated HAT as a public health problem. The other countries that have reached this milestone are Benin, Chad, Côte d’Ivoire, Equatorial Guinea, Ghana, Guinea, Rwanda, Togo and Uganda.
The World Health Organization (WHO) has officially designated Health Canada, the Ministry of Health, Labour and Welfare/Pharmaceuticals and Medical Devices Agency (MHLW/PMDA) of Japan, and the Medicines and Healthcare products Regulatory Agency (MHRA) of the United Kingdom as WHO-Listed Authorities (WLAs), a status granted to national authorities that meet the highest international regulatory standards for medical products.
With these latest designations, WHO expands the growing list of WLAs, now involving 39 agencies across the world, supporting faster and broader access to quality-assured medical products, particularly in low- and middle-income countries (LMICs).
In addition, the Republic of Korea’s Ministry of Food and Drug Safety (MFDS) – one of the first regulatory authorities to complete the WLA assessment for both medicines and vaccines in October 2023 – has had its listing scope successfully expanded, now covering all regulatory functions.
“This recognition reflects the deep commitment of these authorities to regulatory excellence,” said Dr Tedros Adhanom Ghebreyesus, WHO Director-General. “Their designation as WHO-Listed Authorities is not only a testament to their robust regulatory systems but also a critical contribution to global public health. Strong and trusted regulators help ensure that people everywhere have access to safe, effective, and high-quality medical products.”
Around 70% of countries worldwide still face significant challenges due to weak or inadequate regulatory systems for evaluating and authorizing medical products. The WLA framework promotes regulatory convergence, harmonization and international collaboration, allowing WHO Prequalification Programme and regulatory authorities, especially those in LMICs, to rely on the trusted work and decisions of designated agencies. This collaboration supports efficient use of limited resources, enabling better and faster access to quality-assured life-saving medical products to millions more people.
“The principle of reliance is central to WHO’s approach to regulatory systems strengthening and a cornerstone for effective, efficient and smart regulatory oversight of medical products,” said Dr Yukiko Nakatani, WHO Assistant Director-General for Health Systems, Access and Data. “WHO-Listed Authorities are key enablers in promoting trust, transparency, and faster access to quality-assured medical products, especially in low- and middle-income countries.”
In a world where health threats, including substandard and falsified medical products, know no borders, WLAs also serve as critical pillars of preparedness and equity, making life-saving products available more broadly, rapidly and efficiently.
The designations follow a rigorous performance evaluation process carried out by WHO using its globally recognized benchmarking and assessment tools. These evaluations were reviewed by the Technical Advisory Group on WLAs (TAG-WLA), which convened in June 2025.
Canada, Japan and the UK’s regulatory authorities were previously recognized as Stringent Regulatory Authorities (SRAs). Their designation under the WLA framework marks an important step in moving beyond the old SRA system, while ensuring continuity and stability in global procurement processes of quality-assured medical products.
Launched in 2022 to replace the previous SRA model, the WLA initiative provides a transparent and evidence-based pathway for global recognition of regulatory authorities to facilitate regulatory convergence and reliance. It builds on decades of WHO leadership to help countries work together more closely on regulating medical products, speeding up access to safe, effective and quality-assured medical products for people around the world.
Media contacts:
4 August 2025 -- Geneva/New York -- Breastfeeding is one of the most effective ways to ensure a baby’s health, development, and survival in the earliest stages of life. It acts as their first vaccine, providing protection against diseases including diarrhoea and pneumonia.
Investing in breastfeeding is an investment in the future, yet only 48 per cent of infants under six months are exclusively breastfed – well below the World Health Assembly target of 60 per cent by 2030. This is due to the overlapping challenges for new mothers, health workers, and health systems.
Millions of mothers around the world do not receive timely and skilled support in a healthcare setting when they need it most.
Only a fifth of countries include infant and young child feeding training for the doctors and nurses who care for new mothers. This means the majority of the world’s mothers leave hospitals without proper guidance on how to breastfeed their babies and when to introduce complementary feeding.
In many countries, health systems are too often under-resourced, fragmented, or poorly equipped to deliver quality, consistent, evidence-based breastfeeding support.
Investment in breastfeeding support remains critically low even though every dollar invested generates US$35 in economic returns.
As we mark World Breastfeeding Week under the theme, “Prioritize breastfeeding: Create sustainable support systems”, WHO and UNICEF are calling on governments, health administrators, and partners to invest in high-quality breastfeeding support, by:
Strengthening health systems to support breastfeeding is not just a health imperative, it is a moral and economic imperative. WHO and UNICEF remain committed to supporting countries to build resilient health systems that leave no mother or child behind.
About WHO
Dedicated to the well-being of all people and guided by science, the World Health Organization leads and champions global efforts to give everyone, everywhere an equal chance at a safe and healthy life. We are the UN agency for health that connects nations, partners and people on the front lines in 150+ locations – leading the world’s response to health emergencies, preventing disease, addressing the root causes of health issues and expanding access to medicines and health care. Our mission is to promote health, keep the world safe and serve the vulnerable.
About UNICEF
UNICEF, the United Nations agency for children, works to protect the rights of every child, everywhere, especially the most disadvantaged children and in the toughest places to reach. Across more than 190 countries and territories, we do whatever it takes to help children survive, thrive, and fulfil their potential.
Media contacts:
Laura Keenan
Communications officer
World Health Organization
Telephone: +41 79 500 65 64
Email: keenanl@who.int
Nadia Samie-Jacobs
Communication Specialist (Media)
UNICEF
Telephone: +1 845 760 2615
Email: nsamie@unicef.org
WHO HQ media team: mediainquiries@who.int
27 July 2025 - Malnutrition is on a dangerous trajectory in the Gaza Strip, marked by a spike in deaths in July.
Of 74 malnutrition-related deaths in 2025, 63 occurred in July – including 24 children under five, a child over five, and 38 adults. Most of these people were declared dead on arrival at health facilities or died shortly after, their bodies showing clear signs of severe wasting.
The crisis remains entirely preventable. Deliberate blocking and delay of large-scale food, health, and humanitarian aid has cost many lives.
Nearly one in five children under five in Gaza City is now acutely malnourished, as reported by Nutrition Cluster partners. Global Acute Malnutrition (GAM), which measures the percentage of children aged 6–59 months suffering from acute malnutrition, has tripled since June, making it the worst-hit area in the Gaza Strip. In Khan Younis and the Middle Area, rates have doubled in less than one month. These figures are likely an underestimation due to the severe access and security constraints preventing many families from reaching health facilities.
So far in July, over 5000 children under five have already been admitted for outpatient treatment of malnutrition in just the first two weeks, 18% of them with Severe Acute Malnutrition (SAM), the most life-threatening form. This continues a significant rising trend since May, with 6500 children admitted for treatment in June, which is the highest number recorded since October 2023.
An additional 73 children with SAM and medical complications were hospitalized in July, compared to 39 in June, bringing total inpatient admissions in 2025 to 263. This surge in cases is overwhelming the only four specialized malnutrition treatment centres in the Gaza Strip, pushing an already fragile health system closer to collapse. All four centres are working beyond capacity, running low on fuel, with their supplies expected to run out by mid-next month. Health workers are exhausted, and the breakdown of water and sanitation systems is accelerating the spread of disease, driving a dangerous cycle of illness and death.
The crisis is taking a severe toll on pregnant and breastfeeding women. Recent Nutrition Cluster screening data shows that over 40% are severely malnourished. The situation is most critical in the Middle Area, where rates have tripled compared to June, and in Gaza City and Khan Younis, where they have doubled.
It is not only hunger that is killing people, but also the desperate search for food. Families are being forced to risk their lives for a handful of food, often under dangerous and chaotic conditions. Since 27 May, more than 1060 people have been killed and 7200 injured while trying to access food.
WHO calls for urgent, sustained efforts to flood the Gaza Strip with diverse, nutritious food, and to expedite the delivery of therapeutic supplies for children and vulnerable groups, as well as essential medicines and supplies. This flow must remain consistent and unhindered to support recovery and prevent further deterioration. WHO reiterates its call for the protection of civilians and health. WHO also calls for the release of our detained colleague, the release of hostages, and for an immediate ceasefire.
Related: Conflict in Israel and the occupied Palestinian territory and region
Media contacts:
The World Health Organization (WHO) has certified Timor-Leste as malaria-free, a remarkable achievement for a country that prioritized the disease and embarked on a concerted, nation-wide response shortly after gaining independence in 2002.
“WHO congratulates the people and government of Timor-Leste on this significant milestone,” said Dr Tedros Adhanom Ghebreyesus, WHO Director-General. “Timor-Leste’s success proves that malaria can be stopped in its tracks when strong political will, smart interventions, sustained domestic and external investment and dedicated health workers unite.”
With today’s announcement, a total of 47 countries and 1 territory have been certified as malaria-free by WHO. Timor-Leste is the third country to be certified in the WHO South-East Asia region, joining Maldives and Sri Lanka which were certified in 2015 and 2016 respectively.
Certification of malaria elimination is granted by WHO when a country has proven, beyond reasonable doubt, that the chain of indigenous transmission has been interrupted nationwide for at least the previous three consecutive years.
“We did it. Malaria has been one of our most relentless enemies – silent, persistent, and deadly. We lost too many lives to a disease that should be preventable. But our health workers never gave up, our communities held strong, and our partners, like WHO, walked beside us. From 223 000 cases to zero – this elimination honours every life lost and every life now saved. We must safeguard this victory with continued vigilance and community action to prevent malaria's re-entry,” said Dr Élia António de Araújo dos Reis Amaral, SH, Minister of Health, Government of Timor-Leste.
Since gaining independence in 2002, Timor-Leste has made remarkable strides in the fight against malaria – reducing cases from a peak of more than 223 000 clinically diagnosed cases in 2006 to zero indigenous cases from 2021 onwards.
Timor-Leste’s success in eliminating malaria was driven by the Ministry of Health’s swift action in 2003 to establish the National Malaria Programme, a dedicated programme for planning, implementing, and monitoring malaria control efforts nationwide. With only two full-time officers initially, the programme was able to lay the foundation for progress early on through strong technical leadership, managerial capacity and attention to detail.
Within a few years, the country introduced rapid diagnostic tests and artemisinin-based combination therapy as part of the National Malaria Treatment Guidelines and began distributing free long-lasting insecticide treated nets to communities most at risk.
In 2009, with support from the Global Fund to Fight AIDS, Tuberculosis and Malaria, Timor-Leste scaled up nationwide vector control efforts through the distribution of long-lasting insecticide-treated nets and indoor residual spraying. Malaria diagnosis was also expanded using microscopy and rapid diagnostic tests at the point of care across all local health posts.
Facing the challenges of severe shortages of health workers and doctors, Timor-Leste made investments and developed its three-tier health system – comprising national hospitals, reference hospitals, community health centers (CHCs), and health posts – to ensure most residents can access care within an hour's walk. Additionally, citizens are provided with free health services at the point of care, as part of the government’s policy on free universal health care. Monthly mobile clinics and community outreach programmes further enhance health services in rural areas.
Timor-Leste’s success in combating malaria highlights the importance of country leadership and strong collaboration between the Ministry of Health, WHO, local communities, non-governmental organizations, donors, and multiple government sectors. A real-time integrated case-based surveillance system ensures rapid data collection and response, while trained health workers ensure timely detection and screening of malaria cases, including at borders. These integrated efforts have paved the way for the country to be officially certified malaria-free.
"Timor-Leste’s malaria-free certification is a defining national triumph – driven by bold leadership, tireless efforts of health workers, and the resolve of its people. As a young nation, Timor-Leste stayed focused – testing, treating, and investigating swiftly. Ending transmission and maintaining zero deaths takes more than science; it takes grit. This victory protects generations, present and future, and shows what a determined country can achieve,” said Dr Arvind Mathur, WHO Representative to Timor-Leste.
WHO malaria-free certification
The final decision on awarding a malaria-free certification is made by the WHO Director-General, based on a recommendation by the Technical Advisory Group on Malaria Elimination and Certification and validation from the Malaria Policy Advisory Group. More on WHO’s malaria-free certification process.
The World Health Organization (WHO) and the United Nations Office on Drugs and Crime (UNODC) have jointly released a landmark report unveiling critical findings on the persistent and preventable threat of contaminated medicines which claimed the lives and compromised the health of countless patients, predominantly children, through the ingestion of medicines with dangerously high levels of toxic chemicals.
Over the past 90 years, at least 25 documented incidents of excipient contamination have resulted in more than 1300 deaths worldwide, many of them children. These incidents occur often due to systemic vulnerabilities in the global supply chain of pharmaceutical excipients, and they have disproportionately affected people in low- and middle-income countries (LMICs), where regulatory oversight and access to quality-assured medicines may be limited.
Titled “Contaminated medicines and integrity of the pharmaceutical excipients supply chain”, the report highlights a tragic and ongoing public health crisis: the contamination of medicines with industrial-grade toxic chemicals, notably diethylene glycol (DEG) and ethylene glycol (EG).
These substances are used as industrial solvents and antifreeze agents but can cause severe health issues and be fatal if ingested, even in small amounts, especially for children. They are often illegally substituted for pharmaceutical-grade excipients such as propylene glycol, glycerin, and sorbitol—ingredients used in the formulation of medicines, including cough and paracetamol syrups.
Since October 2022, WHO has issued 7 Medical Product Alerts concerning multiple batches of contaminated liquid oral medicines, many of which were marketed for paediatric use and exported widely to LMIC. WHO also issued 2 Alerts concerning falsified bulk chemicals masquerading as pharmaceutical quality excipients.
Following a particularly serious case in The Gambia, in which at least 66 children lost their lives, attention was once again focused on this issue. The case in The Gambia was quickly followed by similar incidents in Indonesia and Uzbekistan with a further 268 reported deaths and two further WHO Medical Product Alerts.
Most of the recent cases involve inexpensive oral liquid medicines that can be bought without a prescription. In most cases these medicines were marketed specifically for children and are registered medicines available in pharmacies, medicine stores or informal street markets.
The report reveals how criminal networks exploit market volatility and regulatory gaps to introduce toxic substitutes into the supply chain. Key findings include:
The report calls for urgent global action to close regulatory gaps, strengthen oversight of excipient supply chains and protect all populations, especially the most vulnerable such as children, from preventable and deadly poisoning.
WHO has long played a central and proactive role in preventing, detecting, and responding to substandard and falsified medical products. This report reinforces the critical importance of strong and effective medicines regulatory systems to ensure access to safe, effective and quality-assured products.
Complementing this public health perspective, UNODC highlights the criminal dimension of the issue, documenting how organized criminal groups falsify documentation, substitute industrial-grade chemicals and exploit digital platforms to illegally infiltrate the global pharmaceutical supply chain with toxic and unregulated substances. Its contribution underscores the importance of criminal justice responses in parallel to regulatory action.
The report underscores the need for:
In many cases, contaminated medicines are the result of intentional criminal conduct. Addressing this threat requires coordinated efforts by all stakeholders, including law enforcement agencies, customs officials, prosecutors and anti-corruption bodies. The report calls for greater cross-border cooperation, investigative capacity and the use of international legal instruments such as the United Nations Convention against Transnational Organized Crime (UNTOC).
WHO and UNODC urge Member States, national regulatory authorities, criminal justice actors, law enforcement agencies, pharmaceutical manufacturers and excipient distributors to take immediate decisive action to prevent further avoidable tragedies. Failure to act now risks condemning future generations of children to the same unacceptable and avoidable harms.
This report is the result of a collaborative effort involving national regulatory authorities (NRAs) and global health partners. Its development was made possible through the generous support of the Fleming Fund and the Gates Foundation.WHO and UNODC extend their sincere appreciation to all stakeholders who contributed to this important work, particularly the NRAs of The Gambia, Indonesia and Pakistan, whose experiences and insights were instrumental in shaping the report’s findings.